Treatment of the feline atopic syndrome - a systematic review.

Abstract

BACKGROUND\nFeline allergic skin disease and asthma occur regularly in small animal practice.\n\n\nOBJECTIVES\nTo provide evidence-based recommendations for small animal practitioners on the treatment of feline atopic syndrome (FAS).\n\n\nMETHODS AND MATERIALS\nThe authors reviewed the literature available before February 2020, prepared a detailed evidence-based literature review and made recommendations based on the evaluated evidence.\n\n\nRESULTS\nSixty-six papers and abstracts were identified describing treatment interventions for FAS and evaluated to establish treatment recommendations. For many treatment options, the papers were retrospective, open studies or case reports.\n\n\nCONCLUSION AND CLINICAL RELEVANCE\nIn this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-specific immunotherapy in feline atopic skin syndrome. Evidence pointed to low-to-moderate efficacy for antihistamines, fatty acids and palmitoyl ethanolamide. In feline asthma, there was good evidence for the efficacy of oral and inhaled glucocorticoids, and limited evidence of moderate efficacy for allergen-specific immunotherapy. Evidence supported low-to-moderate efficacy of mesenchymal stem cells, inhaled lidocaine and oclacitinib as treatments for feline asthma. For almost all therapeutic options (with the exception of glucocorticoids and ciclosporin), more randomised controlled trials are needed.